Nef-IN-B9

CAS No. 1473404-51-1

Nef-IN-B9 ( Nef inhibitor B9 )

Catalog No. M12024 CAS No. 1473404-51-1

Nef-IN-B9 (Nef inhibitor B9) is a small molecule that blocks Nef-dependent Hck activity with IC50 of 2.8 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 170 Get Quote
5MG 260 Get Quote
10MG 408 Get Quote
25MG 672 Get Quote
50MG 945 Get Quote
100MG 1278 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Nef-IN-B9
  • Note
    Research use only, not for human use.
  • Brief Description
    Nef-IN-B9 (Nef inhibitor B9) is a small molecule that blocks Nef-dependent Hck activity with IC50 of 2.8 uM.
  • Description
    Nef-IN-B9 (Nef inhibitor B9) is a small molecule that blocks Nef-dependent Hck activity with IC50 of 2.8 uM, while the activity against Hck alone is >20 uM; also showes weak activity against other Src-family members with IC50 of >20 uM for c-Src, Lck and Lyn; blocks wild-type HIV-1 replication with IC50 of 100-300 nM, and blocks Nef-mediated SFK activation in HIV-infected cells; binds directly to Nef with Kd of 1.79 nM.
  • Synonyms
    Nef inhibitor B9
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1473404-51-1
  • Formula Weight
    402.81
  • Molecular Formula
    C16H11ClN6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (E)-4-((3-chlorophenyl)diazenyl)-5-hydroxy-3-(4-nitrophenyl)-1H-pyrazole-1-carbothioamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Emert-Sedlak LA, et al. Chem Biol. 2013 Jan 24;20(1):82-91.
molnova catalog
related products
  • HMN214

    HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.

  • Dolutegravir interme...

    Dolutegravir intermediate-1 is a new synthetic Dolutegravir intermediate extracted from patent WO 2016125192 A2.

  • BMS-818251

    BMS-818251 (BMS818251) is a novel potent, small-molecule inhibitor of HIV-1 entry with EC50 of 0.019 nM against e laboratory-adapted HIV-1 strain NL4-3.